

Catalyst Clinical Research, a Portfolio Company of QHP Capital, Acquired Genpro Research to Expand Global Footprint and Deepen Service Offerings



The demand for Clinical Research Organizations (CROs) has surged in recent years, with the global market projected to [grow from \\$82 billion in 2023 to \\$188.5 billion by 2030](#), growing at a CAGR of 12.5%. Around 70% of pharmaceutical and biotech companies now outsource their clinical trials to CROs due to the trials' increasing complexity, which has doubled over the past decade. CROs handle approximately 75% of late-stage trials, highlighting their crucial role in the drug development process. The rise of novel therapies and personalized medicine has further fueled the need for CROs, given their specialized knowledge and technological capabilities. The globalization of research and the importance of real-world evidence have also driven demand for CROs' expertise in managing international regulations and leveraging big data for insightful outcomes. As the pharmaceutical and healthcare industries advance, CROs will remain essential partners, streamlining research processes, optimizing trial design, and ensuring compliance. Their pivotal role in driving medical innovation and improving patient outcomes is undeniable.

With a robust market growth forecast and increasingly complex trials, CROs' value in shaping the future of healthcare continues to grow.

Founded in 2016, Genpro Research ("Genpro") is a next-generation services and technology partner for the pharmaceutical, biotechnology, and medical device industries. They are highly regarded in the industry for providing advanced solutions in biostatistics and programming, medical writing, and regulatory submissions. Their advanced approach of using machine learning and natural language processing algorithms to enable process automation made the ideal acquisition for Catalyst to expand their global footprint and broaden and deepen their service offerings.

Crosstree's expertise in the CRO space and deep understanding of Catalyst's strategic goals helped the firm advise Catalyst in identifying Genpro as the ideal transaction partner to expand their capabilities and their presence into the Asia Pacific region.

Crosstree helps clients by leveraging deep market expertise to identify ideal partners that maximize synergies and position clients to achieve their strategic goals.

ABOUT CATALYST



Catalyst (Catalyst) is a clinical research organization (CRO) that provides highly customizable solutions to the global biopharmaceutical industry through two established, branded solutions: Catalyst Oncology and Catalyst Flex. The company provides full-service oncology CRO offerings through Catalyst Oncology and multi-therapeutic Client- or Catalyst-managed functional services through Catalyst Flex. With around 1,000 staff and offices in the United States, Europe, and the Asia-Pacific region, Catalyst's flexible service model is built from more than a decade of listening to customers, devising customer-centric solutions, and helping customers drive breakthrough clinical studies by leveraging expert teams and innovative technologies.

Catalyst is a portfolio company of QHP Capital, a leading healthcare and life sciences investment firm.

ABOUT GENPRO RESEARCH



Genpro Research is a technology and services partner dedicated to serving the pharmaceutical, biotechnology, and medical devices industries. By providing expertise in biostatistics, data sciences, medical writing and evidence synthesis, the focus has been on thoughtful service execution on clinical studies. As an experienced technology provider, Genpro uses artificial intelligence, machine learning, and natural language processing algorithms for clinical development and post-launch activities. Genpro's central commercial platform, "MaiA" is used for evidence generation and study report automation that brings depth and clarity to enable informed decision making.

CROSSTREE'S EXPERTS ARE SPECIALISTS IN THE NUANCES OF HEALTH SCIENCE AND PROVIDE:

- Deep analytics of capabilities and gaps
- Systemized tactical strategies and a road map to success
- Engaged experts in market analysis, financials, and premium valuations
- Targeted and qualified prospects
- Up-to-date industry trend analysis and forecasting

All while prioritizing corporate core values.

MEETING THE NEEDS OF BOTH THE BUYER AND THE SELLER - BY THE NUMBERS AND BEYOND - IS CROSSTREE'S SPECIALTY.

Crosstree's **proven track record** of superior outcomes is the result of balanced, hands-on guidance from start to close. Partner with the leading health science experts today.



JASON LAYTON

Director

jason.layton@crosstreecapital.com

813-578-7109